ATE338121T1 - Von muc-1 abgeleitete peptide - Google Patents

Von muc-1 abgeleitete peptide

Info

Publication number
ATE338121T1
ATE338121T1 AT00965943T AT00965943T ATE338121T1 AT E338121 T1 ATE338121 T1 AT E338121T1 AT 00965943 T AT00965943 T AT 00965943T AT 00965943 T AT00965943 T AT 00965943T AT E338121 T1 ATE338121 T1 AT E338121T1
Authority
AT
Austria
Prior art keywords
muc
polypeptides
peptides
peptides derived
ctl
Prior art date
Application number
AT00965943T
Other languages
English (en)
Inventor
Joyce Taylor-Papadimitriou
Lukas Carl Heukamp
Rienk Offringa
Cornelis Johanna Maria Melief
Bruce Acres
Mireille Thomas
Original Assignee
Transgene Sa
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921242.5A external-priority patent/GB9921242D0/en
Application filed by Transgene Sa, Imp Cancer Res Tech filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE338121T1 publication Critical patent/ATE338121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00965943T 1999-09-08 2000-09-07 Von muc-1 abgeleitete peptide ATE338121T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9921242.5A GB9921242D0 (en) 1999-09-08 1999-09-08 Cancer vaccine and diagnosis
EP99402237 1999-09-10
US18721500P 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
ATE338121T1 true ATE338121T1 (de) 2006-09-15

Family

ID=27240232

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965943T ATE338121T1 (de) 1999-09-08 2000-09-07 Von muc-1 abgeleitete peptide

Country Status (11)

Country Link
US (3) US20050142640A1 (de)
EP (1) EP1210430B1 (de)
JP (1) JP2003510094A (de)
AT (1) ATE338121T1 (de)
AU (1) AU778701B2 (de)
CA (1) CA2383737C (de)
DE (1) DE60030450T2 (de)
DK (1) DK1210430T3 (de)
ES (1) ES2270870T3 (de)
PT (1) PT1210430E (de)
WO (1) WO2001018035A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004212A1 (en) * 1997-12-30 2009-01-01 Franz-Georg Hanisch Tumour vaccines for MUC1-positive carcinomas
EP1257565A4 (de) * 2000-02-01 2005-04-06 Austin Research Inst Von mucin-1 abgeleitete antigene und ihre verwendung in der immuntherapie
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
CA2441809C (en) 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
CA2482596A1 (en) * 2002-04-22 2003-10-30 Dyax Corp. Antibodies specific for mucin polypeptide
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
AU2006274651B2 (en) * 2005-06-28 2012-09-27 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
EP2089423B1 (de) * 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigenspezifische multi-epitop-impfstoffe
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
EP2250189A4 (de) 2008-02-26 2012-07-04 Univ California Gylcopeptide sowie verfahren zu ihrer herstellung und verwendung
RU2539832C2 (ru) 2008-10-17 2015-01-27 Дана-Фарбер Кэнсер Инститьют, Инк. Пептиды цитоплазматического домена белка muc-1 в качестве ингибиторов раковых заболеваний
AU2010253834B2 (en) * 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
EP2374470A1 (de) * 2010-04-08 2011-10-12 Beta Innov Therapeutische Anwendung von Protein Beta-2-M
WO2011140595A2 (en) 2010-05-10 2011-11-17 4G Vaccines Pty Ltd Immunostimulatory and vaccine compositions
CA2825972A1 (en) 2011-02-24 2012-08-30 Oncothyreon Inc. Muc1 based glycolipopeptide vaccine with adjuvant
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
JP6523685B2 (ja) * 2012-01-03 2019-06-05 アメリカ合衆国 Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
EP3269726B1 (de) * 2015-03-09 2025-05-07 Nec Corporation Peptid aus muc1, pharmazeutische zusammensetzung zur behandlung oder vorbeugung von krebs damit, immunitätsinduzierer und verfahren zur herstellung von antigen-präsentierenden zellen
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
EP3903811A1 (de) * 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmazeutische zusammensetzung und verfahren zur induzierung einer immunantwort

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
WO1993024525A1 (en) * 1992-05-26 1993-12-09 Rijksuniversiteit Leiden PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
ATE491465T1 (de) * 1997-05-08 2011-01-15 Oncothyreon Inc Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen
EP1068178A1 (de) * 1998-03-05 2001-01-17 Agouron Pharmaceuticals, Inc. Nicht-peptidische gnrh wirkstoffe
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies

Also Published As

Publication number Publication date
US7892828B2 (en) 2011-02-22
DK1210430T3 (da) 2006-11-20
ES2270870T3 (es) 2007-04-16
PT1210430E (pt) 2006-12-29
US20080227082A1 (en) 2008-09-18
EP1210430A2 (de) 2002-06-05
DE60030450T2 (de) 2007-08-30
US20100255501A1 (en) 2010-10-07
CA2383737A1 (en) 2001-03-15
CA2383737C (en) 2011-01-18
DE60030450D1 (de) 2006-10-12
WO2001018035A2 (en) 2001-03-15
WO2001018035A9 (en) 2002-09-06
JP2003510094A (ja) 2003-03-18
AU778701B2 (en) 2004-12-16
WO2001018035A3 (en) 2001-11-08
AU7651500A (en) 2001-04-10
US20050142640A1 (en) 2005-06-30
EP1210430B1 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
ATE338121T1 (de) Von muc-1 abgeleitete peptide
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
DE69838143D1 (de) Antimikrobielle peptide
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
PT920510E (pt) Quimeras de gnrh-leucotoxina
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE69320967D1 (de) Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
FI961044A0 (fi) Kininogeeni-inhibiittorit
DE68927379D1 (de) Plättchen blockierende peptide
GB9219936D0 (en) Vaccines
ATE256185T1 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
ATE362939T1 (de) Dimere von thrombinpeptidderivaten
ATE412745T1 (de) Antiangiogene peptide vom n-terminus von endostatin
ATE432984T1 (de) Von mage-10 oder mage-8 abgeleitete hla-a2.1- bindende oligopeptide
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
EP1801211A4 (de) Hla bindendes peptid, dieses codierendes dna-fragment und rekombinanter vektor
DE69130675D1 (de) Klonierung und expression eines rhoptry-assoziierten proteins aus p. falciparum
AU2003260546A8 (en) Device for the presentation of peptides or proteins, method for the preparation and use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1210430

Country of ref document: EP